Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. https://doi.org/10.1093/neuonc/noab106
Taslimi S, Ye VC, Zadeh G (2021) Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease. Neurooncol Adv 3:vdab08
Chappe C, Padovani L, Scavarda D et al (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 23:574–583
Myung JK, Cho H, Park CK et al (2012) Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 5:430–436
Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405
Lee D, Cho YH, Kang SY et al (2015) BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. J Surg Oncol 111:359–364
Arita H, Yamasaki K, Matsushita Y et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4:79
Hatae R, Hata N, Suzuki SO et al (2017) A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology. Neuropathology 37:191–199
Park CK, Lee SH, Kim JY et al (2014) Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget 5:3399–3407
Zhang RQ, Shi Z, Chen H et al (2016) Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget 7:5030–5041
Kleinschmidt-DeMasters BK, Aisner DL, Birks DK et al (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37:685–698
Sun K, Zhou X, Li T et al (2021) Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma. Neurosurg Rev. https://doi.org/10.1007/s10143-021-01492-7
Article PubMed PubMed Central Google Scholar
Louis DN, Giannini C, Perry A et al (2021) Glioblastoma, IDH-wildtype. In: WHO Classification of Central nervous system tumours [Internet], 5th edn. International Agency for Research on Cancer, Lyon (France). https://tumourclassification.iarc.who.int/chapters/45
Nakajima N, Nobusawa S, Nakata S et al (2017) BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. Brain Pathol. https://doi.org/10.1111/bpa.12572
Article PubMed PubMed Central Google Scholar
Dono A, Vu J, Anapolsky M et al (2020) Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. J Neurooncol 149:463–472
Johanns TM, Ferguson CJ, Grierson PM et al (2018) Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults with BRAF-mutated high-grade glioma. J Natl Compr Canc Netw 16:4–10
Kaley T, Touat M, Subbiah V et al (2018) BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study. J Clin Oncol 36:3477–3484
Kanemaru Y, Natsumeda M, Okada M et al (2019) Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Acta Neuropathol Commun 7:119
Kushnirsky M, Feun LG, Gultekin SH et al (2020) Prolonged Complete response with combined dabrafenib and trametinib after BRAF Inhibitor failure in BRAF-mutant glioblastoma. JCO Precis Oncol 2020:4
Lin Z, Xu H, Yang R et al (2021) Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report. Anticancer Drugs. https://doi.org/10.1097/cad.0000000000001130
Article PubMed PubMed Central Google Scholar
Qin C, Long W, Zhang C et al (2020) Multidisciplinary therapy managed recurrent glioblastoma in a BRAF-V600E mutant pregnant female: a case report and review of the literature. Front Oncol 10:522816
Robinson GW, Orr BA, Gajjar A (2014) Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14:258
Venkatesh A, Joshi A, Allinson K et al (2021) Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: a case report and literature review. Curr Probl Cancer. https://doi.org/10.1016/j.currproblcancer.2020.100701:100701
Woo PYM, Lam TC, Pu JKS et al (2019) Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. Oncotarget 10:3818–3826
Ebi H, Bando H (2019) Precision oncology and the universal health coverage system in Japan. JCO Precis Oncol 2019:3
Louis DN, Ohgaki H, Wiestler OD et al (2016) WHO classification of tumours of the central nervous system. Revised 4th edition Edition. In: International Agency for Research on Cancer, Lyon
Ishi Y, Takamiya S, Seki T et al (2020) Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas. Brain Tumor Pathol. https://doi.org/10.1007/s10014-020-00369-9
Lim-Fat MJ, Song KW, Iorgulescu JB et al (2021) Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol 152:515–522
McNulty SN, Schwetye KE, Ferguson C et al (2021) BRAF mutations may identify a clinically distinct subset of glioblastoma. Sci Rep 11:19999
Natsumeda M, Chang M, Gabdulkhaev R et al (2021) Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Brain Tumor Pathol. https://doi.org/10.1007/s10014-021-00407-0
Nonoguchi N, Ohta T, Oh JE et al (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126:931–937
Suzuki Y, Takahashi-Fujigasaki J, Akasaki Y et al (2015) BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review. Brain Tumor Pathol. https://doi.org/10.1007/s10014-015-0234-4
Fernandez-Vega I, Quirk J, Norwood FL et al (2014) Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation. Pathol Oncol Res 20:215–220
Tanaka S, Nakada M, Nobusawa S et al (2014) Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. Brain Tumor Pathol 31:172–176
Watanabe N, Ishikawa E, Kohzuki H et al (2020) Malignant transformation of pleomorphic xanthoastrocytoma and differential diagnosis: case report. BMC Neurol 20:21
Joseph DM, O’Neill AH, Chandra RV et al (2017) Glioblastoma presenting as spontaneous intracranial haemorrhage: case report and review of the literature. J Clin Neurosci 40:1–5
Chi AS, Batchelor TT, Yang D et al (2013) BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 31:e233-236
留言 (0)